Lung Adenocarcinoma Patient Harboring EGFR-KDD Achieve Durable Response to Afatinib: A Case Report and Literature Review

Lung Adenocarcinoma Patient Harboring EGFR-KDD Achieve Durable Response to Afatinib: A Case Report and Literature Review

The rapid development of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations including but not limited to exon 19 deletions (19 del) and point mu...

Full description

Bibliographic Details
Main Authors: Lingling Zhao, Zhen Wang, Haiwei Du, Songan Chen, Pingli Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Oncology
Subjects:
afatinib
EGFR-KDD
lung adenocarcinoma
next-generation sequencing
tyrosine kinase inhibitor
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.605853/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.605853/full

Similar Items